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Fast growing malignant cancers represent a major thera-
peutic challenge. Basic cancer research has concentrated efforts 
to determine the mechanisms underlying cancer initiation and 
progression and reveal candidate targets for future therapeutic 
treatment of cancer patients. With known roles in fundamental 
processes required for proper development and function of the 
nervous system, L1-CAMs have been recently identified as key 
players in cancer biology. In particular L1 has been implicated 
in cancer invasiveness and metastasis, and has been pursued as a 
powerful prognostic factor, indicating poor outcome for patients. 
Interestingly, L1 has been shown to be important for the survival 
of cancer stem cells, which are thought to be the source of cancer 
recurrence. The newly recognized roles for L1CAMs in cancer 
prompt a search for alternative therapeutic approaches. Despite 
the promising advances in cancer basic research, a better under-
standing of the molecular mechanisms dictating L1-mediated 
signaling is needed for the development of effective therapeutic 
treatment for cancer patients.
A major obstacle in oncology is the early diagnosis and curative 
therapeutic intervention of locally invasive cancers that rapidly 
disseminate from the primary tumor to form metastases. The stan-
dard treatment for malignant tumors consists of surgical removal 
of the tumor mass followed by chemo- and radiotherapy in order 
to eradicate the remaining cancer cells. Despite such aggressive 
intervention, a population of resistant cancer cells often remains 
intact and is thought to be the source of cancer recurrence.
During the past decades, cancer basic research has focused on 
determining the molecular mechanisms underlying cancer initia-
tion and progression that can provide a basis for the development 
of new and effective therapeutic treatments for cancer patients. An 
important finding was the discovery that cancer onset and devel-
opment are often associated with alterations in the expression of 
cell adhesion molecules, which are likely to stimulate tumor cell 
 invasiveness by signaling mechanisms that enhance cell migration.1 
The L1 family of neural cell adhesion molecules (L1-CAMs), which 
is comprised of four structurally related transmembrane proteins 
L1, CHL1, NrCAM and neurofascin (Fig. 1), is now in the spot-
light of cancer research due to their upregulation in certain human 
tumors. L1-CAMs are transmembrane molecules of the immuno-
globulin superfamily, characterized by an extracellular region of six 
immunoglobulin-like domains and four to five fibronectin type 
III repeats, followed by a highly conserved cytoplasmic domain, 
which is reversibly linked to the cell cytoskeleton through binding 
to ankyrin and ERM proteins (ezrin-radixin-moesin).2 Its multi-
domain structure allows complex heterophilic interactions with 
diverse cell receptors, although homophilic interactions also have a 
crucial role in L1-CAMs mediated signaling.
A wealth of studies has revealed L1-CAMs as pivotal components 
for proper development of the nervous system through regulation 
of cell-cell interactions. L1-CAMs have critical roles in neuronal 
migration and survival, axon outgrowth and fasciculation, synaptic 
plasticity and regeneration after trauma.2 Neither CHL1 nor L1 is 
present on mature astrocytes, oligodendroglia or endothelial blood 
vessel cells in the brain, but CHL1 is upregulated in astrocytes upon 
injury3 and is present on oligodendroglial precursors.4,5 During 
neural development, L1 plays an important role in the migration 
of dopaminergic neuronal cell groups in the mesencephalon and 
diencephalon.6 In the cerebellum, L1 is required for the inward 
migration of granule neurons from the external granular layer 
and cooperates with NrCAM in regulating neuronal positioning.2 
Similarly, CHL1 controls area-specific migration and positioning 
of deep layer cortical neurons in the neocortex.7 In addition to 
its role in neuronal precursor positioning, L1 plays a crucial role 
in axon guidance, which is governed by repellent and attractive 
response mechanisms directed by Ephrins and Semaphorins and 
their receptors (Ephs, Neuropilins, Plexins).2 The importance of 
L1-CAMs in the development and function of the nervous system 
is exemplified by developmental neuropsychiatric disorders that 
are associated with mutation or genetic polymorphisms in genes 
encoding L1 (X-linked mental retardation) and CHL1 (low IQ, 
speech and motor delay). Polymorphisms in L1 and CHL1 genes 
are also associated with schizophrenia, and NrCAM gene polymor-
phisms are linked to autism in some populations.2
Recent studies have described upregulation of L1 in a variety 
of tumor types. Overexpression of L1 correlates with tumor 
progression and metastasis in certain human gliomas,8 melanoma,9 
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ovarian10 and colon carcinomas.11-13 Interestingly, L1 
was found to be present only in cells at the invasive front 
of colon cancers but not in the tumor mass.12 L1 is also 
associated with micrometastasis to both lymph nodes and 
bone marrow in patients bearing other cancers, suggesting 
a potential role in early metastatic spread.11 L1 has now 
been pursued as both a biomarker and a powerful prog-
nostic factor, indicative of poor outcome for patients as 
observed for epithelial ovarian carcinoma10 and colorectal 
cancer.11 More recently, L1 has been shown to be over-
expressed in a small fraction of glioma cells, termed 
glioma stem cells, which are capable of self-renewal and 
generate the diverse cells that comprise the tumor.14 First 
characterized in acute myeloid leukemia,15 cancer stem 
cells have been recently described in a variety of solid 
tumors, including breast cancer, lung cancer and gastro-
intestinal tumors.16 In gliomas, L1 expression was shown 
to be required for maintaining the growth and survival of 
glioma stem cells.14 These findings suggest that L1 may 
be implicated not only in cancer invasiveness but also in 
cancer survival. It will be important to determine if L1 is 
also upregulated in other cancer stem cells as well as to 
define the role of L1-mediated signaling in other cancers. 
Although not extensively investigated, NrCAM has also 
been shown to be overexpressed in glioblastoma cell 
lines and several cases of high grade astrocytoma17 and 
ependymomas.18 Studies are needed to address whether CHL1 and 
neurofascin play analogous roles in cancer onset and progression.
The molecular mechanisms of L1-mediated signaling that 
govern the migration of neuronal precursors and guidance of axons 
during the development of the nervous system may also be used by 
cancer cells to facilitate invasion and cancer progression. Integrins 
are well-characterized cooperative partners for L1-CAMs, and 
signal transduction pathways activated by this complex are known 
to promote cell adhesion and directional motility. L1/integrin-
mediated signaling may converge with growth factor signaling 
networks to promote motility. Like L1, CHL1 cooperates with 
integrins to stimulate migration. All L1-CAMs reversibly engage 
the actin cytoskeleton through a conserved motif FIGQ/AY in 
the cytoplasmic domain that contains a crucial tyrosine residue 
required for binding the spectrin adaptor ankyrin. Phosphorylation 
of the FIGQY tyrosine decreases ankyrin binding, whereas dephos-
phorylation promotes L1-ankyrin interaction. Dynamic adhesive 
interactions controlled by phosphorylation/dephosphorylation 
of the ankyrin motif in L1 family members may enable a cell 
to cyclically attach and detach from the ECM substrate or from 
neighboring cells, thus facilitating migration.1 Another way L1 
promotes cell migration is by stimulating endocytosis of integ-
rins, reducing cell adhesion to the extracellular matrix.19 Thus, 
it is reasonable to speculate that upregulation of L1 in cancer 
may result in increased L1-mediated signaling and, consequently, 
increased cell migration.
L1-CAMs are cleaved by metalloproteases, releasing functionally 
active ectodomain fragments that are laid down as “tracks” on the 
extracellular matrix (ECM). These fragments can cause autocrine 
activation of signal transduction pathways, promoting cell migra-
tion through heterophilic binding to integrins.20 Specifically, L1 
is cleaved constitutively or inducibly by the ADAM family metal-
loproteases (a disintegrin and metalloprotease) ADAM10 and 
ADAM17, which stimulates cell migration and neurite outgrowth 
during brain development.20,21 In colon cancer, L1 colocalizes with 
ADAM 10 at the invasive front of the tumor tissue, suggesting that 
L1 shedding may play a role in cancer invasiveness.12 Similarly, 
CHL1 is shed by ADAM8, which was reported to promote cell 
migration and invasive activity of glioma cells in vitro and is 
highly expressed in human brain tumors including glioblastoma 
multiforme, correlating with invasiveness in vivo.22 Furthermore, 
NrCAM, found in pancreatic, renal and colon cancers, is subject to 
ectodomain shedding,23 but its function in regulating cell migra-
tion or invasion has not yet been studied.
Given the newly recognized roles of L1 in tumor progression, 
a growing body of experimental studies has explored novel thera-
peutic approaches targeting L1-CAMs. Antibody-based therapeutic 
strategies are being pursued to functionally inhibit homophilic and 
heterophilic interactions of cell adhesion molecules to suppress 
tumor invasive motility. L1 monoclonal antibodies reduce in vivo 
growth of human ovarian and colon carcinoma cells in mouse 
xenograft models.13,24,25 L1 targeting using lentiviral-mediated 
short hairpin RNA (shRNA) interference decreases growth and 
survival of glioma stem cells in vitro, suppresses tumor growth, and 
increases survival of tumor-bearing animals.14 These findings raise 
the possibility that L1 represents a cancer stem cell-specific thera-
peutic target for improving the treatment of malignant gliomas and 
other brain tumors. Cancer stem cells represent a potential target 
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Figure 1. L1-CAMs: All have 6 Ig domains and 4–5 FN domains. The 186 kD 
Neurofascin isoform has a mucin-like Pro/Ala/Thr-rich (PAT) domain, while the 155 
kD has only the 4 FN domains. RGD and DGEA motifs interact with integrins, while 
the FIGQ/AY motif binds to ankyrin. ERM binding sites are indicated. The RSLE motif 
in L1 recruits AP2/clathrin adaptor for endocytosis.
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for future treatment of different cancer as these cells are believed to 
be responsible for cancer recurrence.26 Promoting cancer stem cell 
differentiation by drug treatment could potentially reduce stem 
cells properties of self-renewal and proliferation, leading to inhibi-
tion of tumor growth.
Inhibitors of metalloproteases that block L1-CAM shed-
ding represent a potentially novel approach to curtailing tumor 
invasiveness. Chemical inhibitors of ADAMS are appealing for 
glioma therapy due to their diffusability, which circumvents 
blood-brain barrier limitations. Another novel approach involves 
the secreted axon repellent protein, Semaphorin 3A (Sema3A). 
L1-CAMs serve as co-receptors for Sema3A by cis binding in the 
plasma membrane to Neuropilin-1, important for repellent axon 
guidance.2 Interestingly, Sema3A inhibits invasiveness of prostate 
cancer cells27 and migration and spreading of breast cancer cells 
in in vitro assays,28 and thus may also be mediated by L1-CAMs. 
Such an approach could be potentially useful in mitigating inva-
sion of cancer cells in gliomas and other tumors that are known to 
express L1 and Neuropilins. However, effective strategies for some 
types of cancer can promote cancer progression in other types. For 
example, Sema3A has been shown to contribute to the progression 
of pancreatic cancer29 and colon cancer.30 Thus, it is imperative 
that the molecular mechanisms underlying L1-mediated signaling 
are understood in a tissue specific manner. Despite the promising 
advances in cancer basic research, much more research is needed to 
better design strategies for cancer therapy.
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